Nantkwest, inc. (NK)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Operating activities:
Net loss

-18,383

-15,641

-15,581

-16,682

-17,885

-17,340

-23,635

-27,732

-27,519

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-23,969

-23,452

-24,515

-

-31,897

-33,997

-30,677

-26,822

-46,312

-130,893

-32,849

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,217

2,209

2,202

2,206

2,395

2,787

2,776

2,369

1,623

1,569

1,461

1,374

1,162

1,839

770

513

485

491

-5

960

26

Non-cash lease expense related to operating lease right-of-use assets

674

679

659

642

624

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

445

477

277

522

1,351

1,407

3,968

8,934

9,073

8,884

8,714

9,381

10,018

11,266

18,669

23,355

20,562

21,406

38,979

126,313

24,523

Amortization of operating lease right-of-use assets

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of net premiums and discounts on marketable debt securities

-45

-11

12

40

-41

-81

-39

-142

-201

-299

-358

-368

-572

-615

-624

-517

-426

-

-

-

-

Non-cash interest items, net

-17

-73

-110

-158

95

32

-232

58

-149

-72

-178

-217

-253

300

-243

221

295

-

-

-

-

Loss on disposal of assets

-

-

-

-

-

-

-

-

-36

0

-64

0

0

0

0

-3

-15

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-122

-128

-124

-124

-182

-98

-124

-93

-152

-50

-228

-145

-

-

-

-

Loss on sales of marketable debt securities

-1

-

-

-

0

-

-

-

-

-

-

-

-

19

49

23

46

-

-

-

-

Change in value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

483

883

Loss incurred by Inex Bio

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

-57

Gain on settlement of note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

133

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

-105

Prepaid expenses and other current assets

-244

-3,061

4,642

-10,777

-80

-3,851

13,137

-315

847

-732

-730

1,293

13

-

-

-

160

1,768

1,163

371

-71

Operating lease right-of-use assets, net

0

-

-

-

247

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-335

-

-

-

-8

-

-

-

-

6

-12

-326

-126

-78

-237

-175

337

1

-2,399

3,505

87

Operating lease right-of-use assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,270

-

-

-

670

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

1,758

117

-

2,560

-1,792

725

567

237

821

-737

-3,188

1,767

1,949

99

Accrued expenses and other liabilities

997

-

-

-

797

-

-

-

1,878

147

658

-1,538

434

-327

816

402

1,236

1,007

-1,328

2,315

-3

Due to related parties

300

-254

-157

-520

-162

-503

326

-528

20

803

-670

115

1,314

-123

126

53

322

-

-

-

-

Operating lease liabilities

-758

-

-

-

-655

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability, less current portion

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and revenue

-

-

-

-

-

-138

-131

-121

-118

-121

-105

1,467

-40

119

613

527

495

843

-6

-36

-64

Net cash used in operating activities

-12,596

-14,885

-16,572

-16,827

-13,078

-14,033

-17,571

-16,266

-15,511

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-10,057

-

-10,683

-8,301

-8,856

-10,944

-4,199

-2,790

-7,372

Purchases of property, plant and equipment

146

680

413

985

2,104

2,045

3,663

2,492

4,902

11,433

10,717

8,156

4,509

1,358

3,079

1,056

1,067

955

1,134

114

38

Purchase of Viracta common stock

-

-

-

-

-

-

-

-

-

-

-

-

8,500

-

-

-

-

-

-

-

-

Purchase of Viracta common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Purchases of marketable debt securities, available-for-sale

10,300

9,787

10,042

16,516

50,273

12,513

28,754

21,465

32,038

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable debt securities

-

-

-

-

-

-

-

-

-

-

-

-

25,207

-

42,054

54,440

111,397

-

-

-

-

Sales/maturities of marketable debt securities

24,609

22,630

27,829

28,882

32,918

30,080

49,633

45,711

39,860

67,407

46,275

86,286

54,254

58,002

51,988

45,345

10,552

-

-

-

-

Net cash provided by (used in) investing activities

14,163

12,163

17,374

11,378

-19,459

15,914

16,874

21,393

2,920

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Purchase of Inex Bio Inc., net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,818

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

16,038

-

6,855

-10,151

-101,912

-172,120

-651

-597

-1,856

Principal payments of financing/capital lease obligations

-

-

-

-

-

-

-

-

-

64

14,948

4,898

22

22

10

0

0

-

-

-

-

Principal payments of financing lease obligations

-

-

-

-

-

-

137

133

65

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of stock options and warrants

0

0

0

0

39,221

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of common stock with commissions

-

-

-

-

-

-

-

-

-

2,771

0

11,406

1,050

3,949

2,574

6,774

2,550

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

23

-

1

37

1,154

381

185

199

660

-

-

-

110

Net share settlement for restricted stock unit vesting and option exercises

123

61

40

0

26

0

0

80

43

330

0

159

550

514

592

0

0

-

-

-

-

Net cash (used in) provided by financing activities

-123

-61

-40

-501

39,195

-370

-115

-201

-85

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

132

Net cash used in financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-468

-

-2,991

-6,575

-1,890

306

243,079

73,970

-22

Net increase in cash, cash equivalents, and restricted cash

1,444

-2,783

762

-5,950

6,658

1,511

-812

4,926

-12,676

2,952

-18,119

25,443

5,513

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents, and restricted cash at end of period:
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,819

-25,027

-112,658

-182,708

238,179

70,583

-9,250

Supplemental disclosure of cash flow information:
Interest

7

11

5

0

3

258

38

145

34

36

394

201

37

37

29

0

0

-

-

-

-

Income taxes

0

0

0

3

0

0

0

4

0

0

0

3

0

1

0

0

1

-5

5

0

1

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities

182

-114

-1,120

-723

2,031

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Viracta convertible notes and accrued interest into investment in equity securities of Viracta (Note 4)

0

0

0

0

751

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized (losses) gains on marketable debt securities

-23

-13

31

122

118

90

100

107

-174

-205

34

4

70

-608

-456

166

796

-

-

-

-

Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities

-

-

-

-

-

-

-

-

5,930

-

4,159

10,910

2,492

1,661

-967

985

1,074

-

-

-

-

Cashless exercise of stock options

0

0

0

0

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cashless exercise of stock options

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-